logo
Join/ Subscribe Us

Subscribe

We recognize the significance of content in the modern digital world. Sign up on our website to receive the most recent technology trends directly in your email inbox..





    We assure a spam-free experience. You can update your email preference or unsubscribe at any time and we'll never share your information without your consent. Click here for Privacy Policy.


    Safe and Secure

    Free Articles

    logo
    Join/ Subscribe Us

    Subscribe

    We recognize the significance of content in the modern digital world. Sign up on our website to receive the most recent technology trends directly in your email inbox.





      We assure a spam-free experience. You can update your email preference or unsubscribe at any time and we'll never share your information without your consent. Click here for Privacy Policy.


      Safe and Secure

      Free Articles

      Certara

      Certara Appoints Dr. Chris Bouton as Chief Technology Officer to Advance AI in-silico Drug Discovery and Development Platform

      Strengthening technology innovation and leadership of the Certara AI/ML-enabled biosimulation platform used to speed time to market in drug discovery and development

      RADNOR, Pa., July 31, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the appointment of Christopher Bouton, Ph.D., as Chief Technology Officer. In this role, Bouton will lead technology strategy and development of a next-generation integrated model-informed drug development (MIDD) platform, which is enabled by generative AI and advances in biosimulation technology.

      Dr. Bouton was the founder and CEO of Vyasa Analytics, acquired by Certara in 2022. Vyasa provided scalable deep-learning software, which allows Certara software to make new predictions and answer complex questions across structured and unstructured data sources. Chris has led the development of several new Certara AI-based products, including CoAuthor โ„ข, a generative AI product for regulatory and medical writing. Earlier in his career, Chris founded and led Entagen, an enterprise analytics software provider acquired by Thomson Reuters, and started his work in drug development as a computational biologist at Pfizer.

      โ€œChris is a visionary leader who combines expertise in AI with experience in drug discovery and development,โ€ said William F. Feehery, Chief Executive Officer. โ€œHis leadership has been instrumental in expanding the adoption of AI-powered biosimulation and virtual trials, helping clients achieve greater success in bringing new medicines to patients faster and with greater confidence.

      Certaraโ€™s next-generation modeling platform integrates its scientific expertise, broad portfolio of solutions, and AI approaches to increase the efficiency and effectiveness of discovering and developing novel therapeutics.

      โ€œBiosimulation combined with generative AI and machine learning is redefining how new medicines are discovered and developed, and is speeding timelines, reducing costs, and improving success rates,โ€ said Bouton. โ€œLeading Certaraโ€™s technology strategy to build the industryโ€™s most advanced AI and model-informed drug development platform offers a unique opportunity to advance science and deliver better outcomes for patients worldwide.โ€

      About Certara

      Certara accelerates medicines using biosimulation software, technology, and services to transform traditional drug discovery and development. Its clients include more than 2,400 biopharmaceutical companies, academic institutions, and regulatory agencies across 70 countries. Learn more at certara.com.

      Certara Contact:
      Sheila Rocchio
      sheila.rocchio@certara.com

      Media Contact:
      Alyssa Horowitz
      certara@pancomm.com

      Recommended For You:

      Telemedicine: AI and Remote Patient Monitoring

      Popular Post

      b2b marketing automation
      What Will Marketing Automation Bring for the B2B Companies?
      Best Tools to implement successful Industrial IoT
      Best Tools to implement successful Industrial IoT
      Demystifying Data Center Management (DCIM)
      Demystifying Data Center Management (DCIM)


      Scroll to Top